CATALOGO DEI PRODOTTI DELLA RICERCA

Bria, Emilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.967
EU - Europa 5.586
AS - Asia 3.176
SA - Sud America 16
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 9
Totale 14.784
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.948
CN - Cina 2.239
GB - Regno Unito 2.014
SG - Singapore 777
RU - Federazione Russa 573
FR - Francia 559
IT - Italia 494
IE - Irlanda 482
SE - Svezia 469
FI - Finlandia 428
DE - Germania 362
UA - Ucraina 89
KR - Corea 36
BE - Belgio 30
NL - Olanda 25
IN - India 22
CH - Svizzera 20
TR - Turchia 17
CA - Canada 15
IR - Iran 15
EU - Europa 14
JP - Giappone 14
HK - Hong Kong 13
TG - Togo 11
CL - Cile 7
CZ - Repubblica Ceca 7
PL - Polonia 7
VN - Vietnam 7
AU - Australia 6
ID - Indonesia 6
AZ - Azerbaigian 5
PH - Filippine 5
AE - Emirati Arabi Uniti 4
ES - Italia 4
LV - Lettonia 4
BG - Bulgaria 3
EC - Ecuador 3
GR - Grecia 3
LK - Sri Lanka 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
AM - Armenia 2
BO - Bolivia 2
BR - Brasile 2
CM - Camerun 2
CR - Costa Rica 2
DK - Danimarca 2
EG - Egitto 2
LU - Lussemburgo 2
MY - Malesia 2
NO - Norvegia 2
SA - Arabia Saudita 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
CO - Colombia 1
EE - Estonia 1
IL - Israele 1
JM - Giamaica 1
JO - Giordania 1
MX - Messico 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
TH - Thailandia 1
TM - Turkmenistan 1
UZ - Uzbekistan 1
Totale 14.784
Salva come PNG Salva come JPEG
Città #
Southend 1.886
Chandler 1.084
Woodbridge 954
Singapore 670
Ann Arbor 620
Dublin 482
Jacksonville 441
Houston 401
Beijing 399
Ashburn 262
Jinan 246
Lawrence 236
Princeton 236
Wilmington 191
Nanjing 187
Shenyang 154
Hebei 118
New York 100
Tianjin 93
Verona 92
Changsha 75
Ningbo 75
Haikou 70
Helsinki 70
Milan 58
Nanchang 57
Hangzhou 54
Sindelfingen 54
Zhengzhou 54
Jiaxing 48
Guangzhou 47
Taizhou 47
Taiyuan 37
Seoul 36
Seattle 33
Brussels 30
Santa Clara 29
Fuzhou 28
Lanzhou 26
Los Angeles 25
Norwalk 25
Boardman 24
Falls Church 24
Redwood City 24
Dearborn 22
Lancaster 22
Rome 18
Moscow 16
Bologna 15
Chicago 13
Dallas 13
Fairfield 13
Kent 13
Redmond 13
Augusta 12
Düsseldorf 11
Lomé 11
Washington 11
Zurich 11
Detroit 9
Hong Kong 9
San Francisco 9
Tokyo 9
Trento 9
Clearwater 8
London 7
Munich 7
Zanjan 7
Amsterdam 6
Kochi 6
Mountain View 6
San Mateo 6
Auburn Hills 5
Baku 5
Isola della Scala 5
Markgröningen 5
Ardabil 4
Brescia 4
Brugnera 4
Bussolengo 4
Duncan 4
Fremont 4
Groningen 4
Kemerovo 4
Lille 4
Monmouth Junction 4
Padova 4
Renton 4
Riva 4
San Diego 4
Tappahannock 4
Toronto 4
Trieste 4
Xiangfen 4
Athens 3
Brno 3
Cambridge 3
Chaoyang 3
Colombo 3
Florence 3
Totale 10.324
Salva come PNG Salva come JPEG
Nome #
Le linee guida AIOM, ASCO e MASCC-ESMO sull'emesi da chemioterapia e radioterapia: considerazioni e approfondimenti. 165
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 153
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 140
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 140
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 128
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 125
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 125
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 121
Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis 116
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 112
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 111
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 110
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 110
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 110
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 109
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 108
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 105
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 105
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 105
Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 105
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 105
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 103
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 103
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 102
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 102
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 101
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 100
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 100
Adenocarcinoma of the paraurethral glands: a case report 98
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 97
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 95
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 95
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 92
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 91
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 91
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 91
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 88
Clinical meta-analyses of targeted therapies in adenocarcinoma. 86
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients 84
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 84
The development of PARP as a successful target for cancer therapy 83
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 82
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 79
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 79
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 79
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 78
Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology 78
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 78
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 78
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 77
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 77
Clinical meta-analyses of targeted therapies in adenocarcinoma. 76
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 76
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 75
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 75
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 74
Terapia cronomodulata 73
Skin Testing and Hypersensitivity Reactions to Oxaliplatin 73
Molecular Typing of Lung Adenocarcinoma on Cytological Samples in the Next-Generation Sequencing Era 73
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 72
Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers 72
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 72
Comparision of CEA, MCA, CA 15-3 and CA 27-29 in Follow-Up and Monitoring Therapeutic Response in Breast Cancer Patients 71
Castration Resistant Prostate Cancer (CRPC): State of the Art, Perspectives and New Challenges 70
2-weekly docetaxel: issues for clinical practice. 70
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment 70
Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab 69
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 69
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 69
Do immune checkpoint inhibitors need new studies methodology? 69
Chemotherapy in metastatic renal cell carcinoma today? A systematic review. 68
Antiblastic Chemotherapy in the presence of Abdominal Aorta Aneurysm (AAA): guidelines 68
Novel Clinical Prognostic Score Incorporating the Number of Resected Lymph-Nodes to Predict Recurrence and Survival in Non-Small-Cell Lung Cancer. 68
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 68
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 68
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 68
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 67
Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma 67
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 67
eComment. Does resected lymph-node number influence survival in non-small cell lung cancer? 66
Cardiotoxicity and Incidence Of Brain Metastases After Adjuvant Trastuzumab for Early Breast Cancer: The Dark Side of the Moon? A Meta-Analysis of The Randomized Trials. 66
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer 65
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 65
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 65
Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients 64
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 63
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. 63
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 63
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials 62
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 62
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 62
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? 61
Acute emesis: Moderately emetogenic chemotherapy. 61
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 61
Physical activity and exercise in lung cancer care: will promises be fulfilled? 61
Contralateral Solitary Testis Metastasis Antedating Renal Cell Carcinoma: A Case-Report and Review 60
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. 60
The obesity paradox in cancer: clinical insights and perspectives 60
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 60
Sorafenib for lung cancer: is the "Battle" still open ? 59
Totale 8.465
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.729
article - articoli 55.135
book - libri 351
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.243
Totale 117.458
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020962 0 0 0 0 127 133 169 53 114 88 76 202
2020/20211.525 152 528 56 188 219 136 22 14 15 19 153 23
2021/20221.660 104 543 11 157 43 30 27 99 67 41 136 402
2022/20233.118 270 268 318 585 272 753 32 191 288 19 88 34
2023/20241.541 77 112 118 155 220 225 41 191 32 70 229 71
2024/20251.598 234 266 173 799 126 0 0 0 0 0 0 0
Totale 15.022